Congenital Factor VII deficiency
COAGHemab Therapeutics Holdings, Inc.Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Sutacimig (HMB-001) in Congenital Factor VII deficiency. The expected timing is based on the latest available company guidance and may change.
05/21/26:- Sutacimig Ph2 ongoing in congenital Factor VII deficiency; data expected late 2026 or early 2027. 07/14/26:- New preclinical FVIID data showed thrombin generation restoration; Phase 2 study continues toward Late 2026/Early 2027 readout. 08/11/26:- ISTH preclinical data supported sutacimig; Ph2 data expected Late 2026/Early 2027.
Verification
Confirm timing and program details against the company announcement or filing.